VIA
PTGX icon

Virtus Investment Advisers’s Protagonist Therapeutics PTGX Stock Holding History

Virtus Investment Advisers’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
10,593
+7,733
+270% +$808K 0.3% 152
2026
Q1 		$301K Buy
2,860
+70
+3% +$6.2K 0.08% 277
2025
Q4 		$244K Buy
2,790
+770
+38% +$63K 0.07% 341
2025
Q3 		$134K Buy
2,020
+350
+21% +$19.9K 0.04% 394
2025
Q2 		$92.3K Sell
1,670
-2,395
-59% -$115K 0.03% 364
2025
Q1 		$197K Buy
+4,065
New +$170K 0.05% 265

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Virtus Investment Advisers's PTGX Position: Q2 2026 in Review

Virtus Investment Advisers increased its Protagonist Therapeutics (PTGX) stake by 270% in Q2 2026, buying an estimated $808K and bringing the position to 10,593 shares worth $1.3M. The position accounts for 0.3% of the portfolio, ranked #152.

Virtus Investment Advisers first reported a position in PTGX in Q1 2025 and has held it in 6 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Virtus Investment Advisers held 10,593 shares of Protagonist Therapeutics worth $1.3M as of Q2 2026.
  • Virtus Investment Advisers bought 7,733 Protagonist Therapeutics shares in Q2 2026, an estimated $808K.
  • Protagonist Therapeutics made up 0.3% of Virtus Investment Advisers's portfolio in Q2 2026, its #152 holding.
  • Virtus Investment Advisers first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.